Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/27/2008

ign, scope, enrollment and other aspects of current and planned clinical trials and other studies of Arena's or its collaborators' product candidates and compounds; the tolerability, side effects, efficacy and potential of Arena's or its collaborators' product candidates and compounds; the advancement of Arena's R&D efforts; the advancement and content of Arena's pipeline; Arena's collaborations, including expected activities thereunder; expectations relating to the agreements and Arena's relationship with Siegfried; lorcaserin's development, FDA submission and commercialization; financial guidance and assumptions, including relating to partnering and its series B preferred stock; and other statements about Arena's vision, outlook, strategy, preclinical and internal and partnered clinical programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclos
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... September 30, 2014.  Biorem,s complete 2014 third quarter financial statements and ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , 2014 ... 5,281 , 6,715 , 14,476 Gross profit ...
(Date:11/18/2014)... RPS Diagnostics (RPS®) – a ... announces its third annual partnership of the Centers ... About Antibiotics Week from November 17-23. , Get ... designed to highlight the coordinated efforts of CDC, ... for-profit partners to provide education about the importance ...
(Date:11/18/2014)... Urdorf, Switzerland (PRWEB) November 17, 2014 ... range of processes across the pharmaceutical, chemical, and food ... is it so important, and how do pH sensors ... measurement to assist those in process industries with these ... description of pH measurement in the process industries. The ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Alanda ... and Transparency Reporting solutions, announced today that a ... using its Consummate Providerâ„¢ solution in both the ... a Global, SaaS based, Data Quality remediation portal, ... their third party Providers improve their ability to ...
Breaking Biology Technology:Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 2RPS Again Partners with the CDC in Support of the 2014 Get Smart About Antibiotics Week 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2Alanda Software Completes Successful Implementation of Global Data Quality & Vendor Management Solution for Top Tier Global Biopharmaceutical Company 2
... Ontario, Nov. 6 Helix BioPharma Corp. (TSX, FSE: "HBP" ... and chief operating officer, will present at Merriman Curhan Ford,s ... PM at the Sofitel Hotel in New York City. ... product development programs L-DOS47 and Topical Interferon Alpha-2b. The ...
... - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the ... study of intravenous REOLYSIN(R) in patients with sarcomas metastatic ... 15th Annual Connective Tissue Oncology Society Meeting held in ... poster presentation, entitled "A Phase II Study of Intravenous ...
... The endangered black-footed ferrets inhabit prairie dog towns in the ... The prairie dogs are very susceptible to plague ... U.S. Fish & Wildlife Service (FWS) has implemented a ferret ... their formerly native habitat. Unfortunately, plague can sweep through ...
Cached Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2
(Date:11/7/2014)... BURBANK, Calif. , Nov. 7, 2014  In conjunction ... Burbank Police Departments, The Community Foundation of the ... BURBANK DNA JUSTICE PROJECT," a $250,000 initiative to ... successful initial phase. In its first six months of existence, ... desperately needed evidence support for local law enforcement. ...
(Date:11/6/2014)... Insilico Medicine, Inc, a Baltimore-based bioinformatics company focused ... announced a research collaboration with the international leader ... (OTC: CSBR). , "There are many companies utilizing ... Oncology,s TumorGraft technology is unique in a way ... generating vast amounts of valuable data. Our bioinformatic ...
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
Breaking Biology News(10 mins):Community Foundation Of The Verdugos Unveils Campaign To Fund Glendale-Burbank DNA Justice Project 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2
... Stephen Moose has developed a corn plant with enormous potential ... silage, Moose said, due to a greater number of leaves ... energy crop. The gene known as Glossy 15 was ... waxy coating that acts like a sun screen for the ...
... for its health benefits. But now scientists have ... produce medicines for several autoimmune and inflammatory diseases, ... open access journal BMC Biotechnology . ... research organizations have participated in the study as ...
... knows, children love sweet-tasting foods. Now, new research ... indicates that this heightened liking for sweetness has a ... rate. "The relationship between sweet preference and growth ... demands increase. Children are programmed to like sweet ...
Cached Biology News:Doubling a gene in corn results in giant biomass 2Tobacco makes medicine 2Liking sweets makes sense for kids 2
Kit containing MACS equipment and reagents for immunopurification of proteins....
... LCMSsolution software offers an intuitive, ... instrument control, diverse data handling, ... requirements. Comprehensive functions include data ... data management in both standalone ...
... a modern flow cytometer, a scientist can ... labeled with fluorescent probes. However, the emission ... cell labeling are broader than the light ... filters. Thus, the fluorescence signal of a ...
... Sigmas FLAG Immunoprecipitation kit allows a ... of an active FLAG-tagged protein. The ... gel, which is a highly specific ... resin. The use of affinity resin ...
Biology Products: